Acute doxorubicin pulmotoxicity in rats with malignant neoplasm is effectively treated with fullerenol C60(OH)24 through inhibition of oxidative stress

Pharmacological Reports

Volumn 61, Issue 2, 2009, Pages 335-342

  Injac, Rade ^a   Radic, Natasa ^a   Govedarica, Biljana ^a   Perse, Martina ^a   Cerar, Anton ^b   Djordjevic, Aleksandar ^c   Strukelj, Borut ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b INSTITUTE OF PATHOLOGY   (Slovenia)

^c UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

Doxorubicin; Fullerenol; Lung; Oxidative stress; Pulmotoxicity; Rats

Indexed keywords

ANTIOXIDANT; CATALASE; DOXORUBICIN; FULLERENOL; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; LACTATE DEHYDROGENASE; MALONALDEHYDE; METHYLNITROSOUREA; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; FULLERENE DERIVATIVE; FULLEROL C60(OH)24; GLUTATHIONE;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; BREAST CARCINOMA; CONTROLLED STUDY; DRUG RESPONSE; ENZYME ACTIVITY; HISTOPATHOLOGY; LUNG PARENCHYMA; LUNG TOXICITY; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; ANIMAL; DRUG EFFECT; EXPERIMENTAL NEOPLASM; LUNG; METABOLISM; PATHOLOGY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BODY WEIGHT; CATALASE; DOXORUBICIN; FULLERENES; GLUTATHIONE; L-LACTATE DEHYDROGENASE; LUNG; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 67650242669     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70041-6     Document Type: Article

References (40)

1. Adachi T, Nagae T, Ito Y, Hirano K, Sugiura M: Relation between cardiotoxic effect of adriamycin and superoxide anion radical. J Pharmacobiodyn, 1983, 6, 114-123.
2. Aebi H: Catalase in vitro. Methods Enzymol, 1984, 105, 121-126.
3. Armutcu F, Gunb BD, Altin R, Gurel A: Examination of lung toxicity, oxidant/antioxidant status and effect of erdosteine in rats kept in coal mine ambience. Environ Toxicol Pharmacol, 2007, 24, 106-113.
4. Bhalla KS, Wilczynski SW, Abushamma AM, Petros WP, McDonald CS, Loftis JS, Chao NJ et al.: Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support. Am J Respir Crit Care Med, 2000, 161, 17-25.
5. 22 on doxorubicin induced cytotoxicity. Toxicol In vitro, 2004, 18, 629-637.
6. Brusamolino E, Baio A, Orlandi E, Arcaini L, Passamonti F, Griva V, Casagrande W et al.: Long-term events in adult patients with clinical stage IA-IIA nonbulky Hodgkin's lymphoma treated with four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine and adjuvant radiotherapy: A single-institution 15-year follow-up. Clin Cancer Res, 2006, 12, 6487-6493.
7. Cui JX, Li CL, Guo WM, Li YH, Wang CX, Zhang L, Zhang L et al.: Direct comparison of two pegylated liposomal doxorubicin formulations: Is AUC predictive for toxicity and efficacy? J Control Release, 2007, 118, 204-215.
8. De Vita VT, Hellman S, Rosenberg SA, Eds. Principles and Practice of Oncology, 6th edn, Lippincott Williams and Wilkins, Philadelphia, 2001.
9. 24. Oxid Commun, 2004, 27, 806-812.
10. 24 on doxorubicin induced cardiotoxicity in rats. Mater Sci Forum, 2006, 518, 525-529.
11. 24. Toxicol Mech Methods, 2009, 19, 24-28.
12. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D: Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors, Pharmacol Rev, 1999, 51, 691-743.
13. Eisenbeis CF, Winn D, Poelman S, Polsky CV, Rubenstein JH, Olopade OI: A case of pulmonary toxicity associated with G-CSF and doxorubicin administration. Ann Hematol, 2001, 80, 121-123.
14. 3 particles-induced lung tissue injury: role of free radicals. Cancer Lett, 2001, 167, 7-15.
15. 24 through suppresion of oxidative stress. Pharmacol Rep, 2008, 60, 742-749.
16. 24 on a single dose doxorubicin-induced cardiotoxicity in rats with malignant neoplasm. Technol Cancer Res Treat, 2008, 7, 15-26.
17. 24 on a single dose doxorubicin-induced hepatotoxicity in rats with mammary carcinomas. Biomaterials, 2008, 29, 3451-3460.
18. Injac R, Strukelj B: Recent advances in protection against doxorubicin-induced toxicity. Technol Cancer Res Treat, 2008, 7, 497-516.
19. Julicher RH, Sterrenberg L, Haenen GR, Bast A, Noordhoek J: The effect of chronic adryamicin treatment on heart, kidney and liver tissue of male and female rat. Arch Toxicol, 1988, 61, 275-281.
20. Li T, Danelisen I, Bello-Klein A, Singal PK: Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. Cardiovasc Res, 2000, 46, 523-530.
21. Macann A, Bredenfeld H, Muller R-P, Diehl V, Engert A, Eich HT: Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: A report by the German Hodgkin's lymphoma study group. Int J Radiat Oncol Biol Phys, 2008, 70, 161-165.
22. Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM: Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol, 2005, 23, 7614-7620.
23. Matés JM, Sánchez-Jiménez F: Antioxidant enzymes and their implications in pathophysiologic processes. Front Biosci, 1999, 4, 339-345.
24. Matkovics B, Sasvari M, Kotorman M, Varga IS, Hai DQ, Varga C: Further prove on oxidative stress in alloxan diabetic rat tissues. Acta Physiol Hung, 1997/1998, 85, 183-192.
25. Meadors M, Floyd J, Perry MC: Pulmonary toxicity of chemotherapy. Semin Oncol, 2006, 33, 98-105.
26. Meng Z, Qin G, Zhang B, Geng H, Bai Q, Bai W, Liu C: Oxidative damage of sulfur dioxide inhalation on lungs and hearts of mice. Environ Res, 2003, 93, 285-292.
27. Minchin RF, Johnston MR, Aiken MA, Boyd MR: The pharmacokinetics of doxorubicin in isolated lung of dog and main perfused in vivo. J Pharmacol Exp Ther, 1983, 229, 193-198.
28. Minchin RF, Johnston MR, Schuller HM, Aiken MA, Boyd MR: Pulmonary toxicity of doxorubicin administered by in situ isolated lung perfusion in dogs. Cancer, 1988, 61, 1320-1325.
29. Minotti G: NADPH- and adriamycin-dependent microsomal release of iron and lipid peroxidation. Arch Biochem Biophys, 1990, 277, 268-276.
30. 24. Nitric Oxide, 2004, 11, 201-207.
31. Nowak D, Drzewoski J: Anthracycline-induced oxidative stress - its role in the development of cardiac damage. Cancer J, 1996, 9, 296-303.
32. Öz E, Ýlhan MN: Effects of melatonin in reducing the toxic effects of doxorubicin. Mol Cell Biochem, 2006, 286, 11-15.
33. Park MS, Cancio LC, Jordan BS, Brinkley WW, Rivera VR, Dubick MA: Assessment of oxidative stress in lungs from sheep after inhalation of wood smoke. Toxicology, 2004, 195, 97-112.
34. Patch ER, Davis WB: Role of trensferin and ceruloplasmin in antioxidant activity of lung epithelial lining fluid. J Appl Physiol, 1988, 64, 2092-2099.
35. Quiles JL, Huertas JR, Battino M, Mataix J, Ramirez-Tortosa MC: Antioxidant nutrients and adriamycin toxicity. Toxicology, 2002, 180, 79-95.
36. Shull S, Heintz N H, Periasamy M, Manohar M, Janssen YM, Marsh JP, Mossman BT: Differential regulation of antioxidant enzymes in response to oxidants. J Biol Chem, 1991, 266, 24398-24403.
37. Tanak Y, Takahashi K: Cardiac oxygen radical metabolism in adriamycin-induced cardiotoxicity. Jikeikai Med J, 1990, 37, 253-264.
38. Trajkovic S, Dobric S, Djordjevic A, Dragojevic-Simic V, Milovanovic V: Radioprotective efficiency of fullerenol in irradiated mice. Mater Sci Forum, 2005, 494, 549-554.
39. 24 and amifostine in irradiated rats. Colloid Surfaces B, 2007, 58, 39-43.
40. Tsai S-F, Yang C, Liu B-L, Hwang J-S, Ho S-P: Role of oxidative stress in thuringiensin-induced pulmonary toxicity. Toxicol Appl Pharmacol, 2006, 216, 347-353.